Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phoenix
- Development stage
- Preclinical
- Lead developer
- Esperante Development
- Modality
- Small Molecules
01
Overview
Phoenix (ESP301) is a pharmaceutical candidate currently in preclinical development by Esperante Development (formerly Disphar International) for the treatment of Meniere's disease and associated vertigo. The project is part of the company's Life Cycle Management (LCM) and abbreviated New Drug Application (aNDA) portfolio, which typically focuses on the development of value-added medicines, such as new formulations or generic versions of established therapeutic agents. Meniere's disease is a chronic inner ear disorder characterized by episodes of vertigo, tinnitus, and hearing loss; Phoenix is being developed to address these vestibular symptoms.
- Brand names
- Phoenix
Beyond the preview
Go deeper on Phoenix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phoenix.